Sign up Australia
Proactive Investors - Run By Investors For Investors

Neuren Pharmaceuticals granted ASX trading halt pending trial update

The halt will remain in place until Wednesday 22nd March 2017.
no_picture_pai.jpg
Neuren to update on trial

Neuren Pharmaceuticals (ASX:NEU) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Neuren requested the halt pending details regarding Neuren’s Phase 2 clinical trial of trofinetide in Rett syndrome.

The halt will remain in place until the opening of trade on Wednesday 22nd March 2017, or earlier if an announcement is made to the market.



Register here to be notified of future NEU Company articles
View full NEU profile View Profile

Neuren Pharmaceuticals Timeline

Related Articles

shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
Netscientific has its thumbs in a few clinical pies
April 01 2017
The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use